Back to top

Promising Developments and Strategic Advancements Justify Buy Rating for Viridian Therapeutics

BTIG analyst Julian Harrison maintained a Buy rating on Viridian Therapeutics yesterday and set a price target of $61.00. Julian Harrison’s rating ...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Viridian Therapeutics, Inc. (VRDN)